{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T23:40:07Z","timestamp":1748562007897,"version":"3.41.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00228-015-1918-8","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T01:35:27Z","timestamp":1439170527000},"page":"1209-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Model-based meta-analysis of the effects of non-selective and \u03b11-selective GABAA receptor agonists in healthy volunteers"],"prefix":"10.1007","volume":"71","author":[{"given":"Yu-Peng","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru-Jia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"issue":"9","key":"1918_CR1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","volume":"10","author":"U Rudolph","year":"2011","unstructured":"Rudolph U, Knoflach F (2011) Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 10(9):685\u2013697","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1918_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","volume":"28","author":"B Dell\u2019Osso","year":"2013","unstructured":"Dell\u2019Osso B, Lader M (2013) Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 28(1):7\u201320","journal-title":"Eur Psychiatry"},{"issue":"6","key":"1918_CR3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","volume":"3","author":"RM McKernan","year":"2000","unstructured":"McKernan RM, Rosahl TW, Reynolds DS et al (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3(6):587\u2013592","journal-title":"Nat Neurosci"},{"issue":"6755","key":"1918_CR4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, Crestani F, Benke D et al (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401(6755):796\u2013800","journal-title":"Nature"},{"issue":"5489","key":"1918_CR5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","volume":"290","author":"K Low","year":"2000","unstructured":"Low K, Crestani F, Keist R et al (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290(5489):131\u2013134","journal-title":"Science"},{"issue":"4","key":"1918_CR6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0165-6147(00)01646-1","volume":"22","author":"U Rudolph","year":"2001","unstructured":"Rudolph U, Crestani F, Mohler H (2001) GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22(4):188\u2013194","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"1918_CR7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1111\/j.1460-9568.2006.04775.x","volume":"23","author":"HV Morris","year":"2006","unstructured":"Morris HV, Dawson GR, Reynolds DS et al (2006) Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Eur J Neurosci 23(9):2495\u20132504","journal-title":"Eur J Neurosci"},{"issue":"46","key":"1918_CR8","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","volume":"25","author":"R Dias","year":"2005","unstructured":"Dias R, Sheppard WF, Fradley RL et al (2005) Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 25(46):10682\u201310688","journal-title":"J Neurosci"},{"issue":"3","key":"1918_CR9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bjp.0706056","volume":"144","author":"JR Atack","year":"2005","unstructured":"Atack JR, Hutson PH, Collinson N et al (2005) Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA a receptors. Br J Pharmacol 144(3):357\u2013366","journal-title":"Br J Pharmacol"},{"issue":"13","key":"1918_CR10","doi-asserted-by":"crossref","first-page":"8980","DOI":"10.1073\/pnas.142288699","volume":"99","author":"F Crestani","year":"2002","unstructured":"Crestani F, Keist R, Fritschy JM et al (2002) Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A 99(13):8980\u20138985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"1918_CR11","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1523\/JNEUROSCI.22-13-05572.2002","volume":"22","author":"N Collinson","year":"2002","unstructured":"Collinson N, Kuenzi FM, Jarolimek W et al (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 22(13):5572\u20135580","journal-title":"J Neurosci"},{"issue":"9","key":"1918_CR12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2174\/156802611795371314","volume":"11","author":"JR Atack","year":"2011","unstructured":"Atack JR (2011) GABAA receptor subtype-selective modulators. II. Alpha5-selective inverse agonists for cognition enhancement. Curr Top Med Chem 11(9):1203\u20131214","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"1918_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1471-4892(01)00008-X","volume":"1","author":"H Mohler","year":"2001","unstructured":"Mohler H, Crestani F, Rudolph U (2001) GABA(A)-receptor subtypes: a new pharmacology. Curr Opin Pharmacol 1(1):22\u201325","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"1918_CR14","first-page":"28","volume":"2","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CP (2005) Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 66 Suppl 2(6):28\u201333","journal-title":"J Clin Psychiatry 66 Suppl"},{"issue":"3","key":"1918_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1520-6769(199911\/12)25:3<139::AID-NRC3>3.0.CO;2-W","volume":"25","author":"K D\u00e4mgen","year":"1999","unstructured":"D\u00e4mgen K, L\u00fcddens H (1999) Zaleplon displays a selectivity to recombinant GABAA receptors different from zolipdem, zopiclone and benzodiazepines. Neurosci Res Commun 25(3):139\u2013148","journal-title":"Neurosci Res Commun"},{"issue":"1","key":"1918_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.105.096701","volume":"317","author":"RE Petroski","year":"2006","unstructured":"Petroski RE, Pomeroy JE, Das R et al (2006) Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther 317(1):369\u2013377","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1918_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/hup.445","volume":"18","author":"J Montplaisir","year":"2003","unstructured":"Montplaisir J, Hawa R, Moller H et al (2003) Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 18(1):29\u201338","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"1918_CR18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1345\/aph.1A086","volume":"36","author":"AG Israel","year":"2002","unstructured":"Israel AG, Kramer JA (2002) Safety of zaleplon in the treatment of insomnia. Ann Pharmacother 36(5):852\u2013859","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1918_CR19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","volume":"21","author":"SL Haas de","year":"2007","unstructured":"de Haas SL, de Visser SJ, van der Post JP et al (2007) Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 21(4):374\u2013383","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1918_CR20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269881107082108","volume":"22","author":"SL Haas de","year":"2008","unstructured":"de Haas SL, de Visser SJ, van der Post JP et al (2008) Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 22(1):24\u201332","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1918_CR21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881108092595","volume":"23","author":"SL Haas de","year":"2009","unstructured":"de Haas SL, Franson KL, Schmitt JA et al (2009) The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol 23(6):625\u2013632","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1918_CR22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0269881109354928","volume":"25","author":"JR Atack","year":"2011","unstructured":"Atack JR, Hallett DJ, Tye S et al (2011) Preclinical and clinical pharmacology of TPA023B, a GABAA receptor &alpha;2\/&alpha;3 subtype-selective partial agonist. J Psychopharmacol 25(3):329\u2013344","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1918_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","volume":"6","author":"U Rudolph","year":"2006","unstructured":"Rudolph U, Mohler H (2006) GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol 6(1):18\u201323","journal-title":"Curr Opin Pharmacol"},{"key":"1918_CR24","first-page":"416864","volume":"2012","author":"CH Vinkers","year":"2012","unstructured":"Vinkers CH, Olivier B (2012) Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharmacol Sci 2012:416864","journal-title":"Adv Pharmacol Sci"},{"issue":"1","key":"1918_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2125.2002.t01-10-01714.x","volume":"55","author":"SJ Visser de","year":"2003","unstructured":"de Visser SJ, van der Post JP, de Waal PP et al (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55(1):39\u201350","journal-title":"Br J Clin Pharmacol"},{"key":"1918_CR26","first-page":"134523","volume":"2012","author":"X Chen","year":"2012","unstructured":"Chen X, de Haas S, de Kam M et al (2012) An overview of the CNS-Pharmacodynamic profiles of nonselective and selective GABA agonists. Adv Pharmacol Sci 2012:134523","journal-title":"Adv Pharmacol Sci"},{"issue":"11","key":"1918_CR27","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1177\/0269881109106898","volume":"24","author":"SL Haas de","year":"2010","unstructured":"de Haas SL, Schoemaker RC, van Gerven JM et al (2010) Pharmacokinetics, pharmacodynamics and the pharmacokinetic\/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 24(11):1619\u20131629","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1918_CR28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF01063553","volume":"18","author":"SK Gupta","year":"1990","unstructured":"Gupta SK, Ellinwood EH, Nikaido AM et al (1990) Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. J Pharmacokinet Biopharm 18(2):89\u2013102","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"1918_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0091270004269105","volume":"45","author":"K Venkatakrishnan","year":"2005","unstructured":"Venkatakrishnan K, Culm KE, Ehrenberg BL et al (2005) Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol 45(5):529\u2013537","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1918_CR30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0009-9236(95)90070-5","volume":"58","author":"DR Mould","year":"1995","unstructured":"Mould DR, DeFeo TM, Reele S et al (1995) Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Clin Pharmacol Ther 58(1):35\u201343","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1918_CR31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/clpt.1991.122","volume":"50","author":"AL Steveninck van","year":"1991","unstructured":"van Steveninck AL, Schoemaker HC, Pieters MS et al (1991) A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 50(2):172\u2013180","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1918_CR32","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1002\/jps.22093","volume":"99","author":"MA Kamal","year":"2010","unstructured":"Kamal MA, Smith DE, Cook J et al (2010) Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure. J Pharm Sci 99(8):3628\u20133641","journal-title":"J Pharm Sci"},{"issue":"6","key":"1918_CR33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2125.2010.03648.x","volume":"69","author":"C Garcia-Gea","year":"2010","unstructured":"Garcia-Gea C, Ballester MR, Martinez J et al (2010) Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study. Br J Clin Pharmacol 69(6):663\u2013674","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1918_CR34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/030079908X273327","volume":"24","author":"RH Farber","year":"2008","unstructured":"Farber RH, Burke PJ (2008) Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers. Curr Med Res Opin 24(3):837\u2013846","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1918_CR35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.pnpbp.2005.01.013","volume":"29","author":"LM Lucchesi","year":"2005","unstructured":"Lucchesi LM, Braga NI, Manzano GM et al (2005) Acute neurophysiological effects of the hypnotic zolpidem in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 29(4):557\u2013564","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"1918_CR36","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2125.2006.02632.x","volume":"61","author":"RH Hou","year":"2006","unstructured":"Hou RH, Scaife J, Freeman C et al (2006) Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine. Br J Clin Pharmacol 61(6):752\u2013760","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1918_CR37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/clpt.2010.19","volume":"87","author":"P Hoever","year":"2010","unstructured":"Hoever P, de Haas S, Winkler J et al (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 87(5):593\u2013600","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1918_CR38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1468-2982.1998.1807468.x","volume":"18","author":"R Dixon","year":"1998","unstructured":"Dixon R, Hughes AM, Nairn K et al (1998) Effects of the antimigraine compound zolmitriptan (\u2018Zomig\u2019) on psychomotor performance alone and in combination with diazepam in healthy volunteers. Cephalalgia 18(7):468\u2013475","journal-title":"Cephalalgia"},{"issue":"2","key":"1918_CR39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s002130050271","volume":"131","author":"SG Hege","year":"1997","unstructured":"Hege SG, Ellinwood EJ, Wilson WH et al (1997) Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam. Psychopharmacology (Berl) 131(2):101\u2013107","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"1918_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02245243","volume":"118","author":"A Vermeeren","year":"1995","unstructured":"Vermeeren A, Jackson JL, Muntjewerff ND et al (1995) Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. Psychopharmacology (Berl) 118(1):1\u20139","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"1918_CR41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2125.2006.02815.x","volume":"63","author":"R Gomeni","year":"2007","unstructured":"Gomeni R, Merlo-Pich E (2007) Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 63(5):595\u2013613","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1918_CR42","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.euroneuro.2013.03.004","volume":"23","author":"N Goyal","year":"2013","unstructured":"Goyal N, Gomeni R (2013) A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials. Eur Neuropsychopharmacol 23(11):1570\u20131576","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"1918_CR43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/17460440903036073","volume":"4","author":"G Nucci","year":"2009","unstructured":"Nucci G, Gomeni R, Poggesi I (2009) Model-based approaches to increase efficiency of drug development in schizophrenia: a can\u2019t miss opportunity. Expert Opin Drug Discov 4(8):837\u2013856","journal-title":"Expert Opin Drug Discov"},{"key":"1918_CR44","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ. NONMEM User\u2019s Guide \u2013 Part I\u2013VII. Ellicott City, MD: Icon Development Solutions. ed.: 1989\u20132006."},{"issue":"1","key":"1918_CR45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH et al (2011) Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 101(1):72\u201379","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1918_CR46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75(2):85\u201394","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1918_CR47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0031-6997(25)06840-1","volume":"47","author":"W Sieghart","year":"1995","unstructured":"Sieghart W (1995) Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 47(2):181\u2013234","journal-title":"Pharmacol Rev"},{"issue":"4924","key":"1918_CR48","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1126\/science.2551039","volume":"245","author":"DB Pritchett","year":"1989","unstructured":"Pritchett DB, Luddens H, Seeburg PH (1989) Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science 245(4924):1389\u20131392","journal-title":"Science"},{"issue":"3","key":"1918_CR49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A Bond","year":"1974","unstructured":"Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47(3):211\u2013218","journal-title":"Br J Med Psychol"},{"issue":"5","key":"1918_CR50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00228-010-0795-4","volume":"66","author":"XC Zuo","year":"2010","unstructured":"Zuo XC, Zhang BK, Jia SJ et al (2010) Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 66(5):503\u2013509","journal-title":"Eur J Clin Pharmacol"},{"issue":"3\u20134","key":"1918_CR51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000108379","volume":"55","author":"MJ Barbanoj","year":"2007","unstructured":"Barbanoj MJ, Urbano G, Antonijoan R et al (2007) Different acute tolerance development to EEG, psychomotor performance and subjective assessment effects after two intermittent oral doses of alprazolam in healthy volunteers. Neuropsychobiology 55(3\u20134):203\u2013212","journal-title":"Neuropsychobiology"},{"issue":"8","key":"1918_CR52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-006-0155-6","volume":"62","author":"A Tornio","year":"2006","unstructured":"Tornio A, Neuvonen PJ, Backman JT (2006) The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 62(8):645\u2013651","journal-title":"Eur J Clin Pharmacol"},{"issue":"2\u20133","key":"1918_CR53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-2999(01)00851-2","volume":"415","author":"JN Carlson","year":"2001","unstructured":"Carlson JN, Haskew R, Wacker J et al (2001) Sedative and anxiolytic effects of zopiclone\u2019s enantiomers and metabolite. Eur J Pharmacol 415(2\u20133):181\u2013189","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"1918_CR54","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-007-0350-0","volume":"63","author":"TI Saari","year":"2007","unstructured":"Saari TI, Laine K, Bertilsson L et al (2007) Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 63(10):941\u2013949","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1918_CR55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.jcp.0000085407.08426.e1","volume":"23","author":"J Hall","year":"2003","unstructured":"Hall J, Naranjo CA, Sproule BA et al (2003) Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. J Clin Psychopharmacol 23(4):349\u2013357","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1918_CR56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdd.2510050205","volume":"5","author":"G Caille","year":"1984","unstructured":"Caille G, du Souich P, Spenard J et al (1984) Pharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers. Biopharm Drug Dispos 5(2):117\u2013125","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"1918_CR57","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/mol.59.5.1108","volume":"59","author":"AJ Smith","year":"2001","unstructured":"Smith AJ, Alder L, Silk J et al (2001) Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol Pharmacol 59(5):1108\u20131118","journal-title":"Mol Pharmacol"},{"issue":"2","key":"1918_CR58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/026988119500900203","volume":"9","author":"A Patat","year":"1995","unstructured":"Patat A, Perault MC, Vandel B et al (1995) Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers. J Psychopharmacol 9(2):91\u2013101","journal-title":"J Psychopharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1918-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1918-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1918-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T23:00:50Z","timestamp":1748559650000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1918-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1918-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}